Who are Sotalol or Amiodarone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sotalol-or-amiodarone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sotalol or Amiodarone — Competitive Intelligence Brief

Sotalol or Amiodarone (Sotalol or Amiodarone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Class III antiarrhythmic (Sotalol); Class I/II/III/IV antiarrhythmic (Amiodarone). Area: Cardiovascular.

marketed Class III antiarrhythmic (Sotalol); Class I/II/III/IV antiarrhythmic (Amiodarone) Potassium channels (hERG); Beta-adrenergic receptors (Sotalol); Sodium channels, potassium channels, beta-adrenergic receptors, calcium channels (Amiodarone) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Sotalol or Amiodarone (Sotalol or Amiodarone) — Universitaire Ziekenhuizen KU Leuven. Sotalol and Amiodarone are antiarrhythmic drugs that block potassium channels and slow electrical conduction in the heart to restore and maintain normal heart rhythm.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sotalol or Amiodarone TARGET	Sotalol or Amiodarone	Universitaire Ziekenhuizen KU Leuven	marketed	Class III antiarrhythmic (Sotalol); Class I/II/III/IV antiarrhythmic (Amiodarone)	Potassium channels (hERG); Beta-adrenergic receptors (Sotalol); Sodium channels, potassium channels, beta-adrenergic receptors, calcium channels (Amiodarone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Class III antiarrhythmic (Sotalol); Class I/II/III/IV antiarrhythmic (Amiodarone) class)

Universitaire Ziekenhuizen KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sotalol or Amiodarone — Competitive Intelligence Brief. https://druglandscape.com/ci/sotalol-or-amiodarone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab